The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

A roundup of health news includes Mexico's first screwworm myiasis case, rising measles cases in Texas, the launch of a new ...

“Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Dupixent (dupilumab) for the treatment of chronic spontaneous ...

Regeneron Pharmaceuticals ... or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.

Regeneron Pharmaceuticals said it is working to determine a path forward for its treatment of several retinal conditions after the Food and Drug Administration said it didn't agree with the ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License ...